<DOC>
	<DOC>NCT02624986</DOC>
	<brief_summary>This study will evaluate the safety, efficacy, and pharmacokinetics of idasanutlin in combination with obinutuzumab in participants with relapsed or refractory FL or DLBCL. Participants with FL who achieve complete response (CR), partial response (PR), or stable disease (SD) at the end of induction therapy (EOI) will be eligible for post-induction treatment with obinutuzumab.</brief_summary>
	<brief_title>A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Age greater than or equal to (&gt;/=) 18 years Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Histologically documented cluster of differentiation (CD)20positive Bcell lymphoma classified as relapsed or refractory FL or DLBCL after treatment with at least two prior chemoimmunotherapy regimens that included an antiCD20 monoclonal antibody (mAb) and for which no other more appropriate treatment option exists At least one bidimensionally measurable lesion Agreement to remain abstinent or use adequate contraception, among women or men of childbearing potential Known CD20negative status at relapse or progression Prior allogeneic stem cell transplantation (SCT), or autologous SCT within 100 days prior to Day 1 of Cycle 1 Current use of systemic corticosteroids greater than (&gt;) 20 milligrams (mg) prednisone per day (or equivalent), or prior anticancer therapy to include: radioimmunoconjugate within 12 weeks; mAb or antibodydrug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted smallmolecule therapy within 2 weeks prior to Day 1 of Cycle 1 Requirement for chronic anticoagulation Central nervous system (CNS) disease Active infection Positive for human immunodeficiency virus (HIV) or hepatitis B or C Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1 Poor hematologic, renal, or hepatic function Pregnant or lactating women History of progressive multifocal leukoencephalopathy (PML)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>